Clinical trials: Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
People living with chronic obstructive pulmonary disease (COPD) may experience worsening of symptoms such as shortness of breath, cough and wheezing in addition to changes that may be expected for having COPD.
- Trial name
- OPACE (NCT05772013)
- Testing
- Azithromycin Pill
- Where
- United Kingdom
- Volunteers
- 1,311 people
- Sponsor
- Dr Ian B Wilkinson
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic…
- Trial name
- NCT02948582
- Testing
- Glycopyrrolate Inhalation Solution12.5μg, Glycopyrrolate Inhalation Solution 50μg, Glycopyrrolate Inhalation Solution 100μg
- Volunteers
- 42 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Disease, Chronic Obstructive
Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD
Objective: A prospective multicenter randomized controlled trial to assess the efficacy and safety of Xuebijing injection for acute exacerbation of chronic obstructive pulmonary disease(AECOPD).
- Trial name
- NCT02937974
- Testing
- Xuebijing
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Chinese PLA General Hospital
Asthma
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
The objective of this study is to evaluate fluticasone furoate/vilanterol compared with fluticasone furoate alone in subjects with asthma that is uncontrolled on low to mid dose inhaled corticosteroid (ICS) or low dose ICS/ long…
- Trial name
- NCT03363191
- Testing
- Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol
- Sponsor
- GlaxoSmithKline
Chronic Pulmonary Obstructive Disease
Effects of Yoga on Clinical Impact and Psychosocial Aspects of COPD
The aim of this study is to investigate weather the breathing exercises of Yoga are effective in altering clinical impact, anxiety, depression and quality of life in Chronic Obstructive Pulmonary Disease patients.
- Trial name
- NCT02539524
- Testing
- Yoga bhastrika pranayama breathing exercise, Pulmonary Rehabilitation
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- University of Sao Paulo
Chronic Obstructive Pulmonary Disease
Effects of Kinesio Taping Techniques in COPD Patients
Study will investigate effects of two different kinesio taping techniques on pulmonary parameters of patients with COPD.
- Trial name
- NCT04241510
- Testing
- Kinesio Taping
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Muğla Sıtkı Koçman University
Smoke Induced Lung Disease
Ancillary T Cell Based Studies in SPIROMICS
The long-term objectives of this ancillary application are to characterize a subpopulation of smokers with auto-reactive T cell response, to validate immunodiagnostic assays that could detect emphysema, and to find molecular…
- Trial name
- NCT02036190
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Umeclidinium/vilanterol (UMEC/VI) is a combination product under development that is used for the treatment of airflow obstruction in patients with COPD.
- Trial name
- NCT01879410
- Testing
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
- Where
- 72 sites in United States, Chile and 5 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
COPD - Chronic Obstructive Pulmonary Disease, Muscle Atrophy
Progressive Resistance Training of the Extensor Muscle of the Thigh in COPD-patients Hospitalized With an Exacerbation
We want to test the hypothesis, that resistance training by the use of weigth cuffs on the angle can prevent loss or improve the strength of the quadriceps muscle in COPD patients admitted to hospital due to an exacerbation.
- Trial name
- NCT01812460
- Testing
- Intervention-training-group
- Where
- Denmark
- Sponsor
- Frederikssunds Hospital, Denmark
Chronic Obstructive Pulmonary Disease
Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.
Computational Fluid Dynamics (CFD) is a new functional imaging method. Since CFD is very sensitive to detect small changes, it might be worthwhile to study the acute effect of formoterol and budesonide combination therapy…
- Trial name
- NCT01329276
- Testing
- Symbicort® forte Turbohaler®
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
COPD, LUNG DISEASES, OBSTRUCTIVE
Airway Effects of Tiotropium in Patients With COPD
The aim of the study is to investigate the effect of tiotropium from different devices on a panel of small (IOS, MBNW, DLCO, FVC) and large airway (FEV1, PEF) responses in patients with mild-moderate COPD.
- Trial name
- NCT02683668
- Testing
- Handihaler-Tiotropium 18 mcg untrained, Handihaler-Tiotropium 18 mcg trained, Respimat-Tiotropium 5 mcg trained
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease
Warm Homes for Elder New Zealanders
Aim The purpose of this study is to evaluate whether fuel subsidies reduce exacerbations of COPD among people aged over 55, and therefore whether providing such subsidies is a cost-beneficial policy initiative.
- Trial name
- WHEZ (NCT01627418)
- Testing
- Energy Voucher, No intervention : control arm
- Where
- 3 sites in New Zealand
- Volunteers
- 522 people
- Sponsor
- University of Otago
Chronic Bronchitis, Copd Bronchitis
Gala Early Feasibility Study of RheOx
An early feasibility study (EFS) to assess the safety and clinical utility of RheOx on patients with chronic bronchitis in the United States.
- Trial name
- Gala_EFS (NCT03631472)
- Testing
- RheOx
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Gala Therapeutics, Inc.
COPD, Emphysema
Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease
The aim of this study is to investigate the mechanisms whereby lung function is decreased in COPD. The hypothesis is that in diseases such as COPD, inflammatory cells including neutrophils, macrophages and lymphocytes migrate to…
- Trial name
- NCT00147095
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Asthma, Lung Function Decreased
Dietary Intake in Adults From the GA2LEN Folow-up Survey
The Nutrition Study of the GA2LEN Follow-Survey was designed to investigate the association between usual dietary intake and allergic and respiratory outcomes in adults across Europe.
- Conditions
- Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation
- Trial name
- NCT03251157
- Testing
- Dietary intake of various nutrients, foods and biocompounds
- Where
- United States
- Volunteers
- 3,500 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
- Trial name
- NCT01425814
- Testing
- LAS100977, Reference
- Where
- 8 sites in Germany
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.
- Trial name
- NCT03081247
- Testing
- BGF 320/14.4/9.6 µg MDI, BFF 320/9.6 µg
- Sponsor
- Pearl Therapeutics, Inc.
Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany
This investigation is designed to evaluate the performance, comfort and ease of use of the Simplus and Eson masks amongst NIV patients who are currently on Bi-level therapy
- Conditions
- Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease
- Trial name
- NCT02726048
- Testing
- Simplus/Eson
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of Chronic Obstructive Airways Disease
Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation
Background: In chronic obstructive pulmonary disease, the prognosis for patients who have survived an episode of acute hypercapnic respiratory failure due to an exacerbation is poor.
- Conditions
- Chronic Obstructive Pulmonary Disease, Acute Exacerbation of Chronic Obstructive Airways Disease, Chronic Hypercapnic Respiratory Failure
- Trial name
- NCT01513655
- Testing
- LTNIV
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.